Can MGTX sustain its EPS momentum beyond 2024?

**MeiraGTx Holdings (MGTX) is poised to sustain its EPS momentum beyond 2024**, based on several key indicators: 1. **Forecasted Growth**: MeiraGTx is forecasted to grow its earnings and revenue by 43% and 31.8% per annum, respectively. This growth trajectory is a strong indicator of the company's potential to maintain and enhance its EPS in the coming years. 2. **Earnings and Revenue Trends**: Despite a reported net loss of $20.4 million in Q1 2024, the company showed an improvement from a net loss of $30.4 million in Q1 2023. The revenue reported for Q1 2024 was $0.7 million, which is a significant decrease from $3.3 million in Q1 2023. However, this decline did not significantly impact the EPS, which was reported at a loss of $0.32 per share. This suggests that as the revenue grows, the EPS could potentially improve. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |MGTX|MGTX.O|MeiraGTx Holdings|2024 Q1|48.387096774193544|-0.32|185| |MGTX|MGTX.O|MeiraGTx Holdings|2024 Q2|-43.39622641509433|-0.76|185| |MGTX|MGTX.O|MeiraGTx Holdings|2024 Q3|25.67567567567567|-0.55|185| 3. **Investor Confidence and Analyst Ratings**: Despite the challenges, there has been some positive sentiment from analysts and investors. For instance, Los Angeles Capital Management LLC made a new investment in MeiraGTx Holdings in the 1st quarter. Additionally, the company's stock has been given an "outperform" rating by Royal Bank of Canada, which suggests confidence in the company's future prospects. 4. **Financial Outlook**: MeiraGTx expects sufficient capital to fund operations into Q1 2026, not including potential milestone payments. This financial stability could provide the necessary resources for the company to continue its growth trajectory and sustain its EPS momentum. 5. **Clinical Progress and Milestones**: The company has achieved significant clinical development milestones and received a $50 million milestone payment. Such achievements could lead to increased revenue and potentially improve the company's financial performance, including its EPS. In conclusion, while MeiraGTx has faced challenges in terms of revenue and net losses, the company's growth forecasts, investor confidence, financial outlook, and clinical progress suggest that it is well-positioned to sustain its EPS momentum beyond 2024.